Sign Out
Tenofovir Disoproxil Fumarate/Lamivudine/Efavirenz 300 mg/300 mg/400 mg Tablets is a fixed dose combination of tenofovir disoproxil fumarate, lamivudine and efavirenz. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in patients weighing ≥ 35 kg with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy.
The choice of Tenofovir Disoproxil Fumarate/Lamivudine/Efavirenz 300 mg/300 mg/400 mg Tablets to treat antiretroviral experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or the treatment history of the patient.
Consideration should be given to official treatment guidelines for HIV-1 infection (e.g. by WHO).
Continue with Google